CD38
改良兰金量表
医学
免疫学
CD24型
脑炎
免疫系统
调节性B细胞
美罗华
自身免疫性脑炎
视神经脊髓炎
内科学
白细胞介素10
多发性硬化
生物
抗体
病毒
缺血性中风
缺血
遗传学
干细胞
癌症干细胞
癌症
川地34
作者
Yatong Li,Jing Zhang,Lei Liu,Shijun Cui,Hongzan Sun,Hanqiu Jiang,Yanjun Guo,Jingxiao Zhang,XIE Zhu⁃xiao,Jiawei Wang
标识
DOI:10.1007/s10072-023-06624-z
摘要
To detect the alteration of regulatory B cells (Bregs), follicular helper T cells (Tfh), and regulatory T cells (Tregs) frequencies in patients with anti-N-methyl-D-aspartate receptor (anti-NMDAR) encephalitis. Analyze their association with clinical severity and activity, and explore the effects of different immunotherapies on those immune cell subsets.We enrolled 21 patients with anti-NMDAR encephalitis, 22 patients with neuromyelitis optica spectrum disorder (NMOSD), 14 patients with idiopathic intracranial hypertension (IIH), and 20 healthy controls (HC) in our study. The frequencies of various immune cell subsets were determined using flow cytometry.Compared to patients with IIH and HC, the frequencies of CD24hiCD38hi transitional B cells as well as Tregs were significantly lower while the frequency of Tfh was significantly higher in patients with anti-NMDAR encephalitis. The frequency of CD24hiCD38hi transitional B cells was significantly lower in the acute stage than in the recovery stage, and was negatively correlated with the modified Rankin scale (mRS) and the clinical assessment scale for autoimmune encephalitis (CASE). The frequency of CD24hiCD38hi transitional B cells at the last follow-up after rituximab (RTX) treatment was significantly higher than those treated with oral immunosuppressants or untreated. There was no clear difference between anti-NMDAR encephalitis and NMOSD in the above immune cell subsets.We suggested that the frequencies of CD24hiCD38hi transitional B cells and Tregs were decreased while the frequency of Tfh was increased in patients with anti-NMDAR encephalitis. CD24hiCD38hi transitional B cells frequency may be a potential indicator to estimate the disease activity and severity.
科研通智能强力驱动
Strongly Powered by AbleSci AI